MCR

AffyImmune Announces Confirmed Complete Response in Patient with Anaplastic Thyroid Cancer

Retrieved on: 
星期四, 五月 23, 2024
Biotechnology, FDA, Other Health, Health, Pharmaceutical, Oncology, Other Science, Research, Genetics, Science, Clinical Trials, Survival, MD Anderson Cancer Center, Britz, MCR, University, Therapy, Disease, Safety, Cytokine release syndrome, Assistant, Efficacy, Incidence, ATC, ASCO, DLS, Thyroid cancer, Anaplastic thyroid cancer, ADTC, PDTC, DCR, CRS

Notably, a metabolic complete response (mCR) was achieved in one patient with anaplastic thyroid cancer (ATC), the most aggressive form of the disease.

Key Points: 
  • Notably, a metabolic complete response (mCR) was achieved in one patient with anaplastic thyroid cancer (ATC), the most aggressive form of the disease.
  • “We are excited to be the first to demonstrate the potential of autologous CAR T to induce a complete response in a patient with a solid tumor cancer.
  • The confirmed mCR in the AIC100 Phase 1 study is the first known complete response following a single IV dose of autologous CAR T cells observed in any solid tumor cancer type,” said Matt Britz, CEO, AffyImmune.
  • These are aggressive forms of thyroid cancer that currently have limited treatment options and poor patient outcomes.

Clover Health Reports Strong First Quarter 2024 Financial Results; Improves Guidance to Target Full-Year 2024 Adjusted EBITDA Profitability

Retrieved on: 
星期二, 五月 7, 2024
MCR, Insurance, Software, Artificial intelligence, Disease, PPO, Clover Health, Common stock, Physician, Medicare, Share repurchase, Adjustment, GAAP, Growth, Pharmaceutical industry

First, Clover was profitable on an Adjusted EBITDA basis for the first quarter, and we have high confidence in achieving full year 2024 Adjusted EBITDA profitability.

Key Points: 
  • First, Clover was profitable on an Adjusted EBITDA basis for the first quarter, and we have high confidence in achieving full year 2024 Adjusted EBITDA profitability.
  • For the first quarter 2024, total revenue was $346.9 million, with GAAP net loss from continuing operations improving to $23.2 million.
  • Adjusted EBITDA improved to a profit of $6.8 million, as compared to the prior year period loss of $37.5 million.
  • Insurance MCR also continued to significantly improve to 77.9% in the first quarter 2024, as compared to 86.6% in the first quarter 2023.

Walker & Dunlop Closes $155 Million Refinancing for Manhattan’s Lexington Hotel

Retrieved on: 
星期四, 五月 2, 2024
Professional Services, Commercial Building & Real Estate, Lodging, Finance, Construction & Property, Travel, Tourist Attractions, Walker & Dunlop, Starbucks, MCR, Heart, Tourism, Lexington Avenue, 48th Street, Sponsor, Crunch Fitness, The Lexington Hotel NYC, Capital Group Companies, Multimedia, Collection, Lexington Hotel

Walker & Dunlop, Inc. announced today the completion of a $155 million refinancing deal for The Lexington Hotel , a historic landmark in the heart of Midtown Manhattan.

Key Points: 
  • Walker & Dunlop, Inc. announced today the completion of a $155 million refinancing deal for The Lexington Hotel , a historic landmark in the heart of Midtown Manhattan.
  • Acting as the exclusive advisor to Lexington Hotel Owner LLC, a joint venture between MCR, Island Capital Group LLC, and Three Wall Capital, Walker & Dunlop secured the financing through lender Hudson Bay Capital.
  • View the full release here: https://www.businesswire.com/news/home/20240502781850/en/
    Initially completed in 1929, The Lexington Hotel has undergone extensive renovations and conversions over the years, culminating in its transformation into a Marriott Autograph Collection hotel in 2013.
  • Situated within the dynamic market of Midtown East, The Lexington Hotel benefits from its proximity to major office developments and transportation hubs.

Molina Healthcare Reports First Quarter 2024 Financial Results

Retrieved on: 
星期三, 四月 24, 2024
Managed Care, Health, Investment, MCR, Medicaid, Acquisition, Medicare, GAAP, G&A, Growth, Marketplace, Video game

GAAP net income was $5.17 per diluted share for the first quarter of 2024, a decrease of 6% year over year.

Key Points: 
  • GAAP net income was $5.17 per diluted share for the first quarter of 2024, a decrease of 6% year over year.
  • Adjusted net income was $5.73 per diluted share for the first quarter of 2024, a decrease of 1% year over year.
  • The Medicaid MCR for the first quarter of 2024 was 89.7%, in line with the Company’s expectation and normal quarter to quarter trend fluctuations within our guidance.
  • Management will host a conference call and webcast to discuss Molina Healthcare’s first quarter results at 8:00 a.m. Eastern Time on Thursday, April 25, 2024.

MCR and BLT Complete $632 Million Refinancing of 53-Hotel Portfolio

Retrieved on: 
星期五, 四月 19, 2024
Defense, Other Professional Services, Finance, Women, REIT, Professional Services, Men, Contracts, Restaurant, Bar, Other Travel, Family, Lodging, Vacation, Destinations, Travel, Consumer, Other Construction & Property, Residential Building & Real Estate, Small Business, Commercial Building & Real Estate, Construction & Property, Other Retail, Specialty, Food, Beverage, Retail, MCR, Public expenditure, Acquisition, CMBS, Multimedia, Homewood Suites by Hilton, BLT, NOI, TownePlace Suites

Carl Kuehner, Chairman of BLT, remarks, “It is a great achievement to accomplish a refinancing of this size and scope in today’s challenging debt environment.

Key Points: 
  • Carl Kuehner, Chairman of BLT, remarks, “It is a great achievement to accomplish a refinancing of this size and scope in today’s challenging debt environment.
  • The loan was securitized in a single asset, single borrower (“SASB”) CMBS transaction with the portfolio valued at $960 million.
  • Under the stewardship of MCR and BLT, the portfolio achieved over $64 million of NOI on a trailing 12-month basis at closing, up from $55 million NOI in 2021.
  • Since acquisition, MCR and BLT collectively invested over $118 million of capital expenditures into the portfolio across guestroom improvements, public space upgrades and general property maintenance.

Nu:ionic Hydrogen-Producing Microwave Reactor Achieves Commercial Threshold

Retrieved on: 
星期二, 三月 26, 2024
Research, Electricity, Photograph, Methanol, Regional Development Agency (Canada), Natural gas, Innovation Center station, Steam, Atlantic Canada, Carbon, TPD, ACOA, CO2, Hydrogen, Atmosphere, SMR, Photography, ONB, Ammonia, MCR, Boshoff, Renewable energy

This commercial scale, 100kW electrified reactor can be used in many applications for low carbon hydrogen production from various feedstocks, including biogas, natural gas or renewable ammonia.

Key Points: 
  • This commercial scale, 100kW electrified reactor can be used in many applications for low carbon hydrogen production from various feedstocks, including biogas, natural gas or renewable ammonia.
  • The reactor is undergoing rigorous testing and accumulating run time in the company’s Fredericton, New Brunswick Research and Innovation Center.
  • Microwave Catalytic Reformer installation at Nu:ionic’s Research and Innovation Center.
  • The Microwave Catalytic Reformer is an example of an innovative use of industrial microwave technology for natural gas reforming and other applications,” said Jim Tranquilla, President and Chief Technology Officer.

Crestline Announces the Appointment of Leah McFarland to Senior Vice President of Revenue Strategy

Retrieved on: 
星期五, 三月 22, 2024
Revenue management, Partnership, Crestline Hotels & Resorts, Business administration, MCR Hotels, Senior, White Lodging, MCR, Mark Winegardner

Image: Leah McFarland -- download here: https://bit.ly/494Py0E

Key Points: 
  • FAIRFAX, Va., March 22, 2024 (GLOBE NEWSWIRE) -- Crestline Hotels & Resorts, LLC (“Crestline”) announced today the appointment of Leah McFarland to Senior Vice President of Revenue Strategy.
  • Leah joins Crestline from MCR Hotels where she was Vice President of Revenue Management & e-Commerce.
  • In her position with Crestline, Leah will work closely with executive management and is responsible for leading the team that identifies successful revenue strategies and e-Commerce initiatives for maximization of profit with available demand.
  • “Leah's history of excellence in hospitality sales and revenue management spans more than two decades,” said James Carroll, President & CEO of Crestline Hotels & Resorts.

Inside Information: Additional Positive Data from the Phase 1 Part of the BEXMAB Study in Both Higher-Risk HMA-Failed MDS and r/r AML

Retrieved on: 
星期一, 三月 18, 2024
Principal, Nasdaq First North, Survival, ASH, AML, Associate, Webcast, Patient, Acute myeloid leukemia, Doctor of Philosophy, MD, Quality of life, Myelodysplastic syndrome, Faron Pharmaceuticals, HMA, Myelocyte, Society, Helsinki University Central Hospital, Azacitidine, MDS, MCR, FDA, AIM, SAE, Pharmaceutical industry

TURKU, Finland and BOSTON, March 18, 2024 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid cells to activate anti-tumor immunity in hematological and solid tumor microenvironments, today provided further data from patients treated during the Phase 1 part of the ongoing BEXMAB trial that has moved into Phase 2 for higher-risk (HR) myelodysplastic syndrome (MDS) patients failed on previous hypomethylating agent (HMA).

Key Points: 
  • Latest readout of the BEXMAB study shows more responding patients and good durability of remission amongst HR HMA-failed MDS patients.
  • 4/5 of the initial Phase 1 HR HMA-failed MDS patients were still alive after eight months of follow-up.
  • Faron will be hosting a virtual webinar to discuss the additional data tomorrow, Tuesday, 19 March at 11.00 EET/9am GMT.
  • After the already reported 5 HMA-failed HR MDS patients, 3 new HMA-failed HR MDS patients were enrolled, filling the remaining Phase 1 slots.

Clover Health Reports Fourth Quarter and Full Year 2023 Financial Results; Delivers Continued Momentum in Financial Performance and Provides Full-Year 2024 Guidance

Retrieved on: 
星期二, 三月 12, 2024
Insurance, PPO, Clover, Medicare, MCR, Economics, Clover Health

FRANKLIN, Tenn., March 12, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ: CLOV) ("Clover," "Clover Health" or the "Company"), a managed care company focused on physician enablement, today reported financial results for the fourth quarter and full year 2023. Management will host a conference call today at 5:00 p.m. ET to discuss its operating results and other business highlights.

Key Points: 
  • FRANKLIN, Tenn., March 12, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ: CLOV) ("Clover," "Clover Health" or the "Company"), a managed care company focused on physician enablement, today reported financial results for the fourth quarter and full year 2023.
  • For the fourth quarter 2023, the Company reported revenue of $510.3 million and net loss of $70.5 million, with full-year revenue of $2,033.7 million and net loss of $213.4 million.
  • Insurance revenue during the fourth quarter grew by 12% to $303.1 million, and grew by 14% to $1,235.8 million for full-year 2023.
  • Insurance MCR also meaningfully improved to 82.4% in the fourth quarter and 81.2% for full-year 2023, as compared to 92.4% in the fourth quarter 2022 and 91.8% for full-year 2022.

Tachyum Demonstrates Machine Check and Recovery on Prodigy FPGA

Retrieved on: 
星期二, 三月 12, 2024
Technology, Hardware, Artificial Intelligence, Semiconductor, EDAC, Static, Prodigy, SRAM, CAPEX, OPEX, GPU, Memory, HPC, AI, Linux, Static random-access memory, Architecture, DDR, Universal, MCR, Economics, CPU, FPGA, Computer data storage

Tachyum ® today announced the addition of Machine Check and Recovery (MCR) capabilities with the Linux Error Detection and Correction (EDAC) subsystem to the Prodigy® Universal Processor with successful deployment demonstrated as part of the FPGA emulation system.

Key Points: 
  • Tachyum ® today announced the addition of Machine Check and Recovery (MCR) capabilities with the Linux Error Detection and Correction (EDAC) subsystem to the Prodigy® Universal Processor with successful deployment demonstrated as part of the FPGA emulation system.
  • When the degree of Static Random-Access Memory (SRAM) damage is beyond repair, the error detection allows affected computations to be abandoned rather than provide incorrect results.
  • Prodigy provides Double Error Correction and Triple Error Detection (DECTED), which is a key feature to improving uptime, and is complemented by EDAC to enable preventative maintenance.
  • By eliminating the need for expensive dedicated AI hardware and dramatically increasing server utilization, Prodigy reduces CAPEX and OPEX significantly while delivering unprecedented data center performance, power, and economics.